GleamWall
中文EN

SPTX Seaport Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2042347 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets4.8%
Debt / equity0.00x
Current ratio17.48x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue——————
R&D expense$23.89M$24.62M$21.43M$20.45M$13.41M$10.53M
SG&A expense$6.45M$41.19M$6.11M$4.99M$5.06M$5.65M
Operating income-$30.34M-$65.81M-$27.54M-$25.44M-$18.47M-$16.18M
Pretax income-$26.27M-$62.35M-$24.89M-$22.45M-$14.94M-$13.09M
Income tax$127,000$251,000$519,000$95,000$134,000$31,000
Net income-$26.39M-$62.60M-$25.41M-$22.54M-$15.08M-$13.12M
EBITDA-$30.32M-$65.78M-$27.52M-$25.39M-$18.43M-$16.15M
EPS (basic)-0.49-1.78-10.34-9.43-6.40-5.65
EPS (diluted)-0.49-1.78-10.34-9.43-6.40-5.65
Dividends declared per share0.000.000.00———
Weighted avg. shares (diluted)53.53M35.24M2.46M2.39M2.36M2.32M
Balance sheet
Cash & equivalents$61.55M$64.22M$52.91M———
Short-term investments$228.88M$209.09M$129.70M———
Current assets$299.06M$282.18M$188.34M———
PP&E, net$333,000$360,000$386,000———
Total assets$417.62M$441.68M$227.67M———
Current liabilities$17.11M$15.67M$14.22M———
Total liabilities$20.17M$19.08M$17.97M———
Shareholders' equity$397.45M$422.60M-$115.62M-$70.21M-$49.55M-$36.16M
Shares outstanding53.53M53.53M2.60M———
Cash flow statement
Operating cash flow-$22.68M-$26.14M-$20.17M-$15.77M-$15.32M-$20.20M
Capital expenditure$0$0$0$8,000$269,000$54,000
Free cash flow-$22.68M-$26.14M-$20.17M-$15.77M-$15.59M-$20.26M
Investing cash flow$20.11M-$203.50M$27.85M$15.09M-$1.44M-$225.55M
Financing cash flow-$97,000$240.93M-$783,000$1,000$0$0
Depreciation & amortization$27,000$26,000$26,000$54,000$41,000$36,000
Stock-based compensation$2.45M$36.86M$2.57M$1.78M$1.76M$1.62M

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.